Clinical Trial Update: Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens [Phase 2]

View source ↗

Summary

Phase 2 trial of Velcade (bortezomib) in combination with CAELYX (pegylated liposomal doxorubicin) for ovarian cancer patients who failed platinum therapy has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)
• Velcade (bortezomib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Ovarian Cancer | Phase 2 | Status: WITHDRAWN